Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...

Protein conjugate bacterial vaccines for invasive pneumococcal diseases have revolutionized the epidemiology of invasive bacterial disease in young children in most of the developed world ...

Just a month after getting approval for its new pneumococcal vaccine ... Prevnar franchise. The 15-valent conjugate vaccine was at least as effective as Pfizer's 13-valent Prevnar 13 in the ...

Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of its 21-valent pneumococcal conjugate ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...

Uvax Bio, a privately held vaccine developer founded in 2018 as a spin-off from Scripps Research, has appointed chief ...

Advisory Committee on Immunization Practices (ACIP) has lowered the recommended age for pneumococcal vaccination from 65 to ...

Expert Rev Vaccines. 2009;8(8):1051-1061. Simply defined as an extension of the benefit of protection from immunization in those immunized to those unimmunized in a community, herd effect was key ...

recommended the approval of CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae ...